OPTHEA LIMITED - Announcements

0.00%

60.0¢

Market Cap $820.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

OPT	Appendix 2A Update		25/03/21	138.28KB	Share
OPT	Cleansing Notice		25/03/21	156.62KB	Share
OPT	Appendix 2A		25/03/21	231.49KB	Share
OPT	Proposed issue of Securities - OPT		25/03/21	24.33KB	Share
OPT	Opthea Treats First Patient in Phase 3 Trials of OPT-302	PRICE SENSITIVE	15/03/21	159.51KB	Share
OPT	Opthea to Present at Oppenheimer Healthcare Conference		10/03/21	153.47KB	Share
OPT	Change of Director's Interest Notice - MS		05/03/21	198.76KB	Share
OPT	Change of Director's Interest Notice - MB		05/03/21	198.54KB	Share
OPT	Change of Director's Interest Notice - LG		05/03/21	197.15KB	Share
OPT	Change of Director's Interest Notice - JL		05/03/21	195.98KB	Share
OPT	Change of Director's Interest Notice - DS		05/03/21	195.48KB	Share
OPT	Appendix 2A		05/03/21	230.03KB	Share
OPT	Appendix 3G		05/03/21	219.42KB	Share
OPT	Opthea Finalizes Ph 3 Study Designs and Startup Activities	PRICE SENSITIVE	24/02/21	858.73KB	Share
OPT	Opthea Half Year Report and Accounts	PRICE SENSITIVE	22/02/21	631.17KB	Share
OPT	Change in substantial holding		19/02/21	902.31KB	Share
OPT	Opthea to Present at SVB Leerink Healthcare Conference		17/02/21	160.18KB	Share
OPT	Change in substantial holding		16/02/21	461.69KB	Share
OPT	Change in substantial holding		01/02/21	1.88MB	Share
OPT	Becoming a substantial holder		22/01/21	1.09MB	Share
OPT	Results of Meeting		19/01/21	208.46KB	Share
OPT	Ceasing to be a substantial holder		15/01/21	378.08KB	Share
OPT	Becoming a substantial holder		17/12/20	1.03MB	Share
OPT	Notice of General Meeting and Proxy Form		17/12/20	962.07KB	Share
OPT	Ceasing to be a substantial holder		16/12/20	231.29KB	Share
OPT	Change in substantial holding		15/12/20	380.41KB	Share
OPT	Change in substantial holding		15/12/20	1.88MB	Share
OPT	Becoming a substantial holder		10/12/20	1.1MB	Share
OPT	Ceasing to be a substantial holder		07/12/20	403.9KB	Share
OPT	Change in substantial holding		23/11/20	896.23KB	Share
OPT	Change in substantial holding		10/11/20	388.71KB	Share
OPT	Change in substantial holding		09/11/20	1.87MB	Share
OPT	Change in substantial holding		06/11/20	897.11KB	Share
OPT	Change in substantial holding		06/11/20	388KB	Share
OPT	Change in substantial holding		05/11/20	1.87MB	Share
OPT	Change in substantial holding		04/11/20	894.57KB	Share
OPT	Change in substantial holding		02/11/20	368.82KB	Share
OPT	Change in substantial holding		29/10/20	901.96KB	Share
OPT	Opthea Receives A$8.5m R&D Tax Incentive	PRICE SENSITIVE	27/10/20	75.52KB	Share
OPT	Final Director's Interest Notice - GK		23/10/20	179.47KB	Share
OPT	Becoming a substantial holder		23/10/20	1.26MB	Share
OPT	Change in substantial holding		22/10/20	575.76KB	Share
OPT	Becoming a substantial holder		22/10/20	1.71MB	Share
OPT	Ceasing to be a substantial holder		21/10/20	192.56KB	Share
OPT	Opthea Announces Closing of US Initial Public Offering	PRICE SENSITIVE	21/10/20	3.06MB	Share
OPT	Change in substantial holding		20/10/20	125.12KB	Share
OPT	Cleansing Notice		19/10/20	211.74KB	Share
OPT	Appendix 2A		19/10/20	229.84KB	Share
OPT	Proposed issue of Securities - OPT		19/10/20	31.63KB	Share
OPT	Opthea Announces Pricing of US Initial Public Offering	PRICE SENSITIVE	19/10/20	166.78KB	Share
OPT	Trading Halt	PRICE SENSITIVE	16/10/20	240.21KB	Share
OPT	Initial Director's Interest Notice - JL		15/10/20	140.14KB	Share
OPT	Becoming a substantial holder		15/10/20	303.58KB	Share
OPT	Opthea Launches Proposed US Initial Public Offering	PRICE SENSITIVE	12/10/20	162.89KB	Share
OPT	Results of Meeting	PRICE SENSITIVE	12/10/20	471.4KB	Share
OPT	Trading Halt	PRICE SENSITIVE	12/10/20	239.81KB	Share
OPT	Opthea Chairman Address to the 2020 Annual General Meeting		12/10/20	179.91KB	Share
OPT	Opthea to Appoint Dr Jeremy Levin as Chairman of the Board		05/10/20	106.08KB	Share
OPT	Ceasing to be a substantial holder		29/09/20	188.08KB	Share
OPT	Opthea Files Registration Statement for Proposed US IPO	PRICE SENSITIVE	25/09/20	163.45KB	Share
OPT	Change in substantial holding		23/09/20	63.02KB	Share
OPT	Change in substantial holding		22/09/20	247.4KB	Share
OPT	Initial Director's Interest Notice - DS		15/09/20	139.84KB	Share
OPT	Notice of Annual General Meeting and Proxy Form		11/09/20	778.02KB	Share
OPT	Appendix 4G and Corporate Governance Statement 2020		11/09/20	522.83KB	Share
OPT	Annual Report 2020		11/09/20	4.05MB	Share
OPT	Opthea Appoints US-Based Non-Executive Director		10/09/20	105.7KB	Share
OPT	Opthea Full Year Financial Report 2020	PRICE SENSITIVE	28/08/20	568.56KB	Share
OPT	Opthea Announces Plans for Potential US listing and IPO	PRICE SENSITIVE	24/08/20	150.51KB	Share
OPT	Opthea Completes Successful FDA and EMA Meetings for Phase 3	PRICE SENSITIVE	21/08/20	109.45KB	Share
OPT	Opthea Key Opinion Leader Symposium Presentation		06/08/20	2.89MB	Share
OPT	Opthea to Host Key Opinion Leader Symposium on wAMD and DME		28/07/20	100.08KB	Share
OPT	Initial Director's Interest Notice - LG		27/07/20	156.98KB	Share
OPT	Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)	PRICE SENSITIVE	27/07/20	1.34MB	Share
OPT	Opthea Presents New Data from Ph 1b/2a DME Trial at ASRS	PRICE SENSITIVE	27/07/20	293.79KB	Share
OPT	Opthea Appoints New Non-Executive Director		24/07/20	104.26KB	Share
OPT	Opthea to Present OPT-302 DME Clinical Data at ASRS 2020		23/07/20	126.69KB	Share
OPT	Change in substantial holding		26/06/20	74.78KB	Share
OPT	Change in substantial holding		22/06/20	570.16KB	Share
OPT	Opthea Added to the S&P/ASX 300 Index		22/06/20	91.54KB	Share
OPT	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
OPT	Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME	PRICE SENSITIVE	10/06/20	255.38KB	Share
OPT	Opthea to Host Investor Teleconference		09/06/20	183.67KB	Share
OPT	Trading Halt	PRICE SENSITIVE	09/06/20	240.52KB	Share
OPT	Change in substantial holding		02/06/20	78.44KB	Share
OPT	Change in substantial holding		05/05/20	101.3KB	Share
OPT	Change in substantial holding		16/04/20	78.95KB	Share
OPT	Becoming a substantial holder		31/03/20	254.76KB	Share
OPT	Opthea Completes Patient Dosing in Phase 2a DME Trial	PRICE SENSITIVE	30/03/20	174.45KB	Share
OPT	Ceasing to be a substantial holder from MUFG		26/03/20	375.6KB	Share
OPT	Ceasing to be a substantial holder from MS		26/03/20	900.53KB	Share
OPT	Becoming a substantial holder from MUFG		24/03/20	423.84KB	Share
OPT	Becoming a substantial holder from MS		24/03/20	4.74MB	Share
OPT	Ceasing to be a substantial holder		18/03/20	199.63KB	Share
OPT	Change in substantial holding		18/03/20	90.42KB	Share
OPT	Becoming a substantial holder		13/03/20	1.06MB	Share
OPT	Opthea Half Year Report and Accounts	PRICE SENSITIVE	26/02/20	1.39MB	Share
OPT	Opthea to Present at SVB Leerink Healthcare Conference		17/02/20	65.7KB	Share
OPT	Ceasing to be a substantial holder		16/01/20	427.46KB	Share
OPT	Becoming a substantial holder		09/01/20	702.63KB	Share

OPT Appendix 2A Update
25/03/21		138.28KB	Share
OPT Cleansing Notice
25/03/21		156.62KB	Share
OPT Appendix 2A
25/03/21		231.49KB	Share
OPT Proposed issue of Securities - OPT
25/03/21		24.33KB	Share
OPT Opthea Treats First Patient in Phase 3 Trials of OPT-302
15/03/21	PRICE SENSITIVE	159.51KB	Share
OPT Opthea to Present at Oppenheimer Healthcare Conference
10/03/21		153.47KB	Share
OPT Change of Director's Interest Notice - MS
05/03/21		198.76KB	Share
OPT Change of Director's Interest Notice - MB
05/03/21		198.54KB	Share
OPT Change of Director's Interest Notice - LG
05/03/21		197.15KB	Share
OPT Change of Director's Interest Notice - JL
05/03/21		195.98KB	Share
OPT Change of Director's Interest Notice - DS
05/03/21		195.48KB	Share
OPT Appendix 2A
05/03/21		230.03KB	Share
OPT Appendix 3G
05/03/21		219.42KB	Share
OPT Opthea Finalizes Ph 3 Study Designs and Startup Activities
24/02/21	PRICE SENSITIVE	858.73KB	Share
OPT Opthea Half Year Report and Accounts
22/02/21	PRICE SENSITIVE	631.17KB	Share
OPT Change in substantial holding
19/02/21		902.31KB	Share
OPT Opthea to Present at SVB Leerink Healthcare Conference
17/02/21		160.18KB	Share
OPT Change in substantial holding
16/02/21		461.69KB	Share
OPT Change in substantial holding
01/02/21		1.88MB	Share
OPT Becoming a substantial holder
22/01/21		1.09MB	Share
OPT Results of Meeting
19/01/21		208.46KB	Share
OPT Ceasing to be a substantial holder
15/01/21		378.08KB	Share
OPT Becoming a substantial holder
17/12/20		1.03MB	Share
OPT Notice of General Meeting and Proxy Form
17/12/20		962.07KB	Share
OPT Ceasing to be a substantial holder
16/12/20		231.29KB	Share
OPT Change in substantial holding
15/12/20		380.41KB	Share
OPT Change in substantial holding
15/12/20		1.88MB	Share
OPT Becoming a substantial holder
10/12/20		1.1MB	Share
OPT Ceasing to be a substantial holder
07/12/20		403.9KB	Share
OPT Change in substantial holding
23/11/20		896.23KB	Share
OPT Change in substantial holding
10/11/20		388.71KB	Share
OPT Change in substantial holding
09/11/20		1.87MB	Share
OPT Change in substantial holding
06/11/20		897.11KB	Share
OPT Change in substantial holding
06/11/20		388KB	Share
OPT Change in substantial holding
05/11/20		1.87MB	Share
OPT Change in substantial holding
04/11/20		894.57KB	Share
OPT Change in substantial holding
02/11/20		368.82KB	Share
OPT Change in substantial holding
29/10/20		901.96KB	Share
OPT Opthea Receives A$8.5m R&D Tax Incentive
27/10/20	PRICE SENSITIVE	75.52KB	Share
OPT Final Director's Interest Notice - GK
23/10/20		179.47KB	Share
OPT Becoming a substantial holder
23/10/20		1.26MB	Share
OPT Change in substantial holding
22/10/20		575.76KB	Share
OPT Becoming a substantial holder
22/10/20		1.71MB	Share
OPT Ceasing to be a substantial holder
21/10/20		192.56KB	Share
OPT Opthea Announces Closing of US Initial Public Offering
21/10/20	PRICE SENSITIVE	3.06MB	Share
OPT Change in substantial holding
20/10/20		125.12KB	Share
OPT Cleansing Notice
19/10/20		211.74KB	Share
OPT Appendix 2A
19/10/20		229.84KB	Share
OPT Proposed issue of Securities - OPT
19/10/20		31.63KB	Share
OPT Opthea Announces Pricing of US Initial Public Offering
19/10/20	PRICE SENSITIVE	166.78KB	Share
OPT Trading Halt
16/10/20	PRICE SENSITIVE	240.21KB	Share
OPT Initial Director's Interest Notice - JL
15/10/20		140.14KB	Share
OPT Becoming a substantial holder
15/10/20		303.58KB	Share
OPT Opthea Launches Proposed US Initial Public Offering
12/10/20	PRICE SENSITIVE	162.89KB	Share
OPT Results of Meeting
12/10/20	PRICE SENSITIVE	471.4KB	Share
OPT Trading Halt
12/10/20	PRICE SENSITIVE	239.81KB	Share
OPT Opthea Chairman Address to the 2020 Annual General Meeting
12/10/20		179.91KB	Share
OPT Opthea to Appoint Dr Jeremy Levin as Chairman of the Board
05/10/20		106.08KB	Share
OPT Ceasing to be a substantial holder
29/09/20		188.08KB	Share
OPT Opthea Files Registration Statement for Proposed US IPO
25/09/20	PRICE SENSITIVE	163.45KB	Share
OPT Change in substantial holding
23/09/20		63.02KB	Share
OPT Change in substantial holding
22/09/20		247.4KB	Share
OPT Initial Director's Interest Notice - DS
15/09/20		139.84KB	Share
OPT Notice of Annual General Meeting and Proxy Form
11/09/20		778.02KB	Share
OPT Appendix 4G and Corporate Governance Statement 2020
11/09/20		522.83KB	Share
OPT Annual Report 2020
11/09/20		4.05MB	Share
OPT Opthea Appoints US-Based Non-Executive Director
10/09/20		105.7KB	Share
OPT Opthea Full Year Financial Report 2020
28/08/20	PRICE SENSITIVE	568.56KB	Share
OPT Opthea Announces Plans for Potential US listing and IPO
24/08/20	PRICE SENSITIVE	150.51KB	Share
OPT Opthea Completes Successful FDA and EMA Meetings for Phase 3
21/08/20	PRICE SENSITIVE	109.45KB	Share
OPT Opthea Key Opinion Leader Symposium Presentation
06/08/20		2.89MB	Share
OPT Opthea to Host Key Opinion Leader Symposium on wAMD and DME
28/07/20		100.08KB	Share
OPT Initial Director's Interest Notice - LG
27/07/20		156.98KB	Share
OPT Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)
27/07/20	PRICE SENSITIVE	1.34MB	Share
OPT Opthea Presents New Data from Ph 1b/2a DME Trial at ASRS
27/07/20	PRICE SENSITIVE	293.79KB	Share
OPT Opthea Appoints New Non-Executive Director
24/07/20		104.26KB	Share
OPT Opthea to Present OPT-302 DME Clinical Data at ASRS 2020
23/07/20		126.69KB	Share
OPT Change in substantial holding
26/06/20		74.78KB	Share
OPT Change in substantial holding
22/06/20		570.16KB	Share
OPT Opthea Added to the S&P/ASX 300 Index
22/06/20		91.54KB	Share
OPT S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
OPT Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
10/06/20	PRICE SENSITIVE	255.38KB	Share
OPT Opthea to Host Investor Teleconference
09/06/20		183.67KB	Share
OPT Trading Halt
09/06/20	PRICE SENSITIVE	240.52KB	Share
OPT Change in substantial holding
02/06/20		78.44KB	Share
OPT Change in substantial holding
05/05/20		101.3KB	Share
OPT Change in substantial holding
16/04/20		78.95KB	Share
OPT Becoming a substantial holder
31/03/20		254.76KB	Share
OPT Opthea Completes Patient Dosing in Phase 2a DME Trial
30/03/20	PRICE SENSITIVE	174.45KB	Share
OPT Ceasing to be a substantial holder from MUFG
26/03/20		375.6KB	Share
OPT Ceasing to be a substantial holder from MS
26/03/20		900.53KB	Share
OPT Becoming a substantial holder from MUFG
24/03/20		423.84KB	Share
OPT Becoming a substantial holder from MS
24/03/20		4.74MB	Share
OPT Ceasing to be a substantial holder
18/03/20		199.63KB	Share
OPT Change in substantial holding
18/03/20		90.42KB	Share
OPT Becoming a substantial holder
13/03/20		1.06MB	Share
OPT Opthea Half Year Report and Accounts
26/02/20	PRICE SENSITIVE	1.39MB	Share
OPT Opthea to Present at SVB Leerink Healthcare Conference
17/02/20		65.7KB	Share
OPT Ceasing to be a substantial holder
16/01/20		427.46KB	Share
OPT Becoming a substantial holder
09/01/20		702.63KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $820.7M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED - Announcements

Announcements

Top Stories